Back

Has post-COVID-19 increased CTEPD rates? A prospective study on persistent dyspnea and risk factors

1 September 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Venous thromboembolism Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Leila Alajbegovic

Medical University of Vienna, Vienna (Austria)

7 More presentations in this session

Presentation thumbnail
Impact of reasons for discontinuing anticoagulation therapy on clinical outcomes in patients with venous thromboembolism: insight from the COMMAND VTE Registry-2
Doctor M. Kinugawa (Toyonaka, JP)
Abstract Slides Video
Presentation thumbnail
Statin therapy for the prevention of venous thromboembolism in cancer patients: a systematic review and meta-analysis
Doctor F. Catalani (Bellinzona, CH)
Abstract Slides Video
Presentation thumbnail
Impact of thrombocytopenia on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT Study
Doctor Y. Miyoshi (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
The predictive value of estimated glucose disposal rate for the risk of venous thromboembolism in elderly individuals: a prospective cohort study of UK biobank
Doctor Y. Zheng (Tianjin, CN) Doctor T. Liu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Comparison of hospital and home treatment for symptomatic proximal deep vein thrombosis: from theCOMMAND VTE Registry-2
Mr K. Mushiake (Kurashiki, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Venous thromboembolism

The Event

Event poster

ESC Congress 2025

1 September 2025 11:15 CET
You may be interested in
thumbnail
Congress Session
Diagnosis and therapy of chronic thromboembolic pulmonary hypertension
thumbnail
Congress Presentation
Diagnosis of chronic thromboembolic pulmonary disease from an intensive pulmonary embolism treatment center
thumbnail
Congress Presentation
Cardiopulmonary long-term effects 6, 18 and 30 months after severe COVID-19 infection

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources